# Vertex Enters $10B Deal to Acquire Crinetics Pharmaceuticals

> ma · REPORTED · 2026-07-11

Vertex Pharmaceuticals announced a approximately $10 billion acquisition of Crinetics Pharmaceuticals, in one of the largest biotech M&A transactions of 2026, significantly expanding Vertex's endocrine and rare disease pipeline.

About Vertex Pharmaceuticals: Vertex Pharmaceuticals is a global biotechnology company specializing in treatments for serious diseases including cystic fibrosis, sickle cell disease, and rare conditions, serving patients worldwide.

- Company: Vertex Pharmaceuticals
- Sector: biotech
- Primary source: https://lifesciencedaily.news/weekly-news-roundup-13-july-2026/

---
Source: MedFuel Intel news monitor. Verification tier: REPORTED. Informational only, not investment advice. Corrections: media@medfuelinc.com.